This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): Lilly Gamma Secretase Inhibitor, LY450139
Description: LY450139 is a gamma secretase inhibitor. Gamma secretase is an enzyme involved in the processing of amyloid precursor protein into amyloid beta, a primay toxic culprit in Alzheimer's disease. Inhibition of gamma secretase lowers production of amyloid beta. Gamma secretase is also involved, however, in the processing of Notch protein, and possibly other substrates.
Deal Structure: In August 1998, Elan and Eli Lilly ended the research collaboration they had initiated in 1988 to discover and develop drugs to treat Alzheimers disease. Elan has granted Lilly an exclusive, worldwide license under certain patents to make, have made, use and sell any compound owned by Elan and discovered during the exclusive collaboration, that reduces, via certain mechanisms, beta-amyloid peptide, the principal component of the amyloid plaque which is one of the hallmarks of Alzheimers disease. Elan retains certain commercial rights under the collaboration agreement. If Eli Lilly decides to move forward commercially, Elan has the right to opt in (at no cost) to co-promote LY450139 to neurologists in the US. Elan will also get an undisclosed worldwide royalty.
Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6...See full deal structure in Biomedtracker
Partners: Perrigo Company PLC
Additional information available to subscribers only: